[The PROMISE study : confirmation of effectiveness of benralizumab in severe eosinophilic asthmatic patients].

Benralizumab is a monoclonal antibody directed toward the α subunit of the interleukin-5 receptor. This drug has been established as a key treatment for severe hypereosinophilic asthma. Here we report results of the PROMISE study, an observational study conducted in 73 severe asthmatic patients treated at the asthma clinic of CHU Liège and whose blood eosinophil count was > 300/µl.

[Health promotion and prevention : what role for community pharmacists ?].

Belgian community pharmacists play a pivotal role in both primary and tertiary preventive health activities. Their involvement extends beyond the pharmaceutical care associated with dispensing to include innovative services such as medication review. Additionally, they offer therapeutic education sessions to patients as part of the «Good Use of Medicines» programme.